Kelun Pharmaceutical adjusts shareholder returns, fund management, and governance

Sichuan Kelun Pharmaceutical’s board of directors and supervisory board approved a revised management system for the use of raised funds, along with amendments to the company's articles of association. This includes updating definitions for legal representatives and advanced management, refining procedures for share repurchase, and granting the board authority to approve specific matters without shareholder approval. The company is proposing a mid-year dividend of RMB 1.26 per 10 shares, totaling RMB 200,438,432.21, representing 20.03% of its net profit attributable to shareholders for the first half of 2025. This proposal is contingent on shareholder approval.

Additionally, the company will utilize idle raised funds of up to RMB 1.25 billion to temporarily supplement working capital for 12 months. This is aimed at improving fund efficiency and reducing financial costs, with a commitment to return the funds to a dedicated account by the deadline. The board also approved the establishment of a dedicated account for this purpose and authorized the signing of the regulatory agreement. The updated policies, effective upon shareholder approval, streamline governance and enhance financial flexibility.